Skip to content

Clinical study on the reversal of indolent B cell lymphoma with fuzheng Huatuanjiedu decoction

Clinical study on the reversal of indolent B cell lymphoma with fuzheng Huatuanjiedu decoction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037503
Enrollment
Unknown
Registered
2020-08-28
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inert B cell lymphoma

Interventions

Sponsors

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Patients with indolent B-cell lymphoma conforming to the above diagnosis by Traditional Chinese and western medicine do not need to receive western medicine treatment for their condition evaluation; 2. Aged 18 and 80 years old; 3. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who meet the diagnostic criteria but are complicated with serious organic diseases such as heart, liver, kidney, brain and other malignant tumors are not eligible for the authors; 2. Those who are allergic to the drugs used, have adverse reactions or are in critical condition; 3. Participants in other clinical trials at the same time.

Design outcomes

Primary

MeasureTime frame
Flow cytometry;LDH;Beta 2 microglobulin;ferritin;cytokines;

Secondary

MeasureTime frame
Routine blood;Liver and kidney function;

Countries

China

Contacts

Public ContactXu Wen

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine

1754338172@qq.com+86 13917178588

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026